Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

5 Drug Hopefuls That Are Going to Change Your Life: Part 2

By Sean Williams - Nov 23, 2012 at 6:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's not just about revenue, it's about changing the quality of life!

Every year, the promise of safer and more effective drugs coming to market gives an aging population hope. According to the Phrma organization's website, roughly $49 billion was spent on researching some 2,900 compounds last year alone. The truly amazing part is that we've only touched the tip of the iceberg on what diseases are left to be researched and/or cured. We still have a long way to go with regards to cancer research, and many rare diseases still have largely unmet needs.

Each week for a total of five weeks, I'm going to look at an upcoming drug that has every indication of being not only a revenue blockbuster, but a true life changer. Keep in mind that none of the five drug hopefuls I'll be highlighting are approved by the Food and Drug Administration, so there are plenty of obstacles left to be encountered, including safety data, which could still stand in the way of an ultimate approval.

Last week, I examined Biogen Idec's BG-12 as the first drug hopeful that's set to change people's lives. This week, I want to take a closer look at Gilead Sciences ( GILD 0.22% ) sofosbuvir.

The name sofosbuvir might not strike a chord with many of you because you may know it better as GS-7977, the experimental hepatitis-C drug acquired by Gilead when it purchased Pharmasset for $11 billion late last year. By all respects, sofosbuvir has performed better than anyone could have hoped for in clinical trials, but that hasn't been the case for Gilead's competitors.

Bristol-Myers Squibb ( BMY 0.53% ) tried to follow Gilead's lead and buy its way to success by purchasing Inhibitex for $2.5 billion in January. I claimed the purchase a foolish (with a small 'f') idea since Inhibitex's lead hepatitis-C drug was only through early stage clinical trials. True to form, that purchase wound up biting Bristol in the behind in early August when it disclosed that BMS-986094 (the experimental drug acquired with its Inhibitex purchase) caused the death of a patient and complications with multiple others. BMS-986094 was soon permanently shelved, and Bristol wrote down $1.8 billion on its purchase.

Subsequent to Bristol's troubles, Idenix Pharmaceuticals (NASDAQ: IDIX) also ran into trouble of its own. As a maker of nucleotide-based inhibitors, the FDA placed a clinical hold on two of Idenix's hepatitis-C compounds due to potential safety concerns. Idenix has evaluated the safety of its lead compound, IDX-184 and found no evidence of any safety issues, but the clinical holds still remain.

That leads us back to Gilead's sofosbuvir, which was recently combined with GS-5885 and an antiviral ribavirin in a late-stage trial and found to eliminate all detectable levels of the hepatitis C virus in 100% of patients tested four weeks after a 12-week dosing regimen. This isn't the first time Gilead sofosbuvir has proven effective, either. In a combination with Bristol's daclatasvir in mid-stage trials, sofosbuvir eliminated all detectable levels of the disease in in 100% of genotype 1 patients, and 91% in genotype 2 and 3.

On top of sofosbuvir's success in clinical trials, the simple fact that it's an all-oral treatment lends hope that patients will be privy to far fewer side effects than the current standard treatments offered by Vertex Pharmaceuticals ( VRTX 0.08% ) with Incivek, and Merck ( MRK -1.55% ) with Victrelis. These current standards are given with interferon, a protein that's given intravenously and known to cause flu-like symptoms for up to 48 weeks during treatment. Sofosbuvir's side effects have shown to be far less severe and abate much more quickly than those associated with interferon.

The market for hepatitis C is huge and could equal as much as $20 billion by 2015, according to analysts at Credit Suisse. According to Barclays analyst Tony Butler, given FDA approval, sofosbuvir could hit peak sales of $3.8 billion, so it's not difficult to understand why so many biotechs want a piece of the hepatitis C pie.

Despite Bristol and Idenix's struggles, there are still plenty of viable competitors including: Abbott Laboratories ( ABT -0.04% ) which recently reported a 97% success rate in removing detectable levels of the hepatitis C virus with a three drug combination, as well as ribavirin, in mid-stage trials, and Achillion Pharmaceuticals ( ACHN ) which recently announced proof-of-concept data for its non-nucleotide-based early stage inhibitor, ACH-3102. Yet, it's Gilead's sofosbuvir that has the clear path to approval and the chance to really make a difference in people's lives.

Be sure to check back next week when I unveil the third pipeline drug capable of changing your life for the better.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$69.65 (0.22%) $0.15
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$205.22 (0.08%) $0.16
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$72.28 (-1.55%) $-1.14
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$57.13 (0.53%) $0.30
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$132.42 (-0.04%) $0.05
Achillion Pharmaceuticals, Inc. Stock Quote
Achillion Pharmaceuticals, Inc.
ACHN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.